All pharmacists must be effective medication information providers regardless of their practice. As defined by the New Mexico Conference, an effective provider perceives, assesses, and evaluates medication information needs and retrieves, evaluates, communicates, and applies data from the published literature and other sources as an integral component of patient care. If the profession is to be successful in accepting patient care responsibilities, all pharmacists must have a certain minimum level of skill to survive in the changing practice environment. Developing the skills of an effective medication information provider is the foundation for the pharmacist to be a lifelong learner and problem solver. The literature is a valuable component of both of these processes and will allow the individual pharmacist to adapt to the needs of a continually changing health care system.
Opportunities abound for pharmacists to use medication information skills in all practice settings either as a generalist or a specialist practitioner. There is still the need for the practitioner to have support from drug information centers to meet special information needs, to serve as a resource on effective medication use, and to assist pharmacy practitioners as well as others in solving medication therapy situations. Individuals with special training as medication information specialists will still be needed to operate the centers and to provide leadership in the area of drug informatics, institutional drug policy, poison control, pharmaceutical industry, and in academia.
References
1. Parker PF. The University of Kentucky drug information center. Am J Hosp Pharm. 1965;22:42–7.
2. Amerson AB, Wallingford DM. Twenty years' experience with drug information centers. J Hosp Pharm. 1983;40:1172–8.[PMID: 6881155]
3. Walton CA. The problem of communicating clinical drug information. J Hosp Pharm. 1965;22:458–63.
4. Lowe HJ, Barnett GO. Understanding and using the medical subject headings (MESH) vocabulary to perform literature searches. JAMA. 1994;271:1103–18.[PMID: 8151853]
5. Institute of Medicine. Health professions education: a bridge to quality. Washington, DC: National Academy Press; 2003.
6. Mehnert RB. A world of knowledge for the nation's health: The U.S. National Library of Medicine. J Hosp Pharm. 1986;43:2991–7.[PMID: 3544826]
7. Walton CA. Education and training of the drug information specialist. Drug Intell. 1967;1:133–7.
8. Francke DE. The role of the pharmacist as a drug information specialist. J Hosp Pharm. 1966;23:49.[PMID: 5907110]
9. Koumis T, Cicero LA, Nathan JP, Rosenberg JM. Directory of pharmacist-operated drug information centers in the United States—2003. J Health Syst Pharm. 2004;61:2033–42.[PMID: 15509126]
10. Rosenberg JM, Koumis T, Nathan JP, Cicero LA, McGuire H. Current status of pharmacist-operated drug information centers in the United States. J Health Syst Pharm. 2004;61:2023–32.[PMID: 15509125]
11. Drug topics red book. Montvale(NJ). Medical Economics; 2004.
12. Kinky DE, Erush SC, Laskin MS, Gibson GA. Economic impact of a drug information service. Ann Pharmacother. 1999;33:11–6.[PMID: 9972378]
13. LaFleur J, Tyler LS, Sharma RR. Economic benefits of investigational drug services at an academic institution. Am J Health Syst Pharm. 2004;61:27–32.[PMID: 14725117]
14. Study Commission on Pharmacy. Pharmacists for the future. Ann Arbor (MI): Health Administration Press; 1975. p. 139.
15. Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm. 1990;47:533–50.[PMID: 2316538]
16. American Society of Health-System Pharmacists. ASHP guidelines on the provision of medication information by pharmacists. Am J Health Syst Pharm. 1996;53:1843–5.
17. Kohn LT, Corrigan JM, Donaldson MS. To err is human: building a safer health care system. Washington, DC: National Academy Press; 1999.
18. Vioxx (rofecoxib) information [monograph on the Internet]. Washington: Food and Drug Administration; 2005 [accessed 2007 Jan 18]. Available from: http://www.fda.gov/cder/drug/infopage/vioxx/default.htm
19. Stricker BH, Psaty BM. Detection, verification, and quantification of adverse drug reactions. BMJ. 2004;329:44–7.[PMID: 15231627]
20. Landis NT. ADE rate uncertain, reporting systems inadequate, GAO tells legislators. Am J Health Syst Pharm. 2000;57:515–9.[PMID: 10754757]
21. Grissinger M. Adverse drug reactions: documentation is important, but communication is critical. P&T. 2004;29:5.
22. ASHP guidelines on adverse drug reaction monitoring and reporting. Am J Health Syst Pharm. 1995;52:417–9.
23. Fink JL, Vivian JC, Keller RK, editors. Pharmacy law digest. St Louis (MO): Facts and Comparisons; 1999.
24. FDA issues regulation prohibiting sale of dietary supplements containing ephedrine alkaloids and reiterates its advice that consumers stop using these products [monograph on the Internet]. Washington: Food and Drug Administration; 2004 Feb 6 [accessed 2007 Jan 18]. Available from: http://www.fda.gov/bbs/topics/NEWS/2004/NEW01021.html
25. FDA letter warning health care professionals about kava. Available from: http://www.fda.gov/medwatch/safety/2001/kava.htm
26. Ansani NT, Ciliberto NC, Freedy T. Hospital policies regarding herbal medicines. Am J Health Syst Pharm. 2003;60:367–70.[PMID: 12625219]
27. Wachter RM. The end of the beginning: patient safety five years after "To Err Is Human." Health Aff [serial on the Internet]. 2004 Nov 30 [accessed 2007 Jan 18]: [about 9 p.]. Available from: http://content.healthaffairs.org/cgi/content/full/hlthaff.w4.534/DC1.
28. Johnson ST, Wordell CJ. Internet utilization among medical information specialists in the pharmaceutical industry and academia. Drug Inf J. 1998;32:547–54.
29. Malone PM, Young WW, Malesker MA. Wide area network connecting a hospital drug informatics center with a university. Am J Health Syst Pharm. 1998;55:1146–50.[PMID: 9626377]
30. Berland GK, Elliott MN, Morales LS, Algazy JL, Kravitz RL. Health information on the Internet: accessibility, quality, and readability in English and Spanish. JAMA. 2001;285:2612–21.[PMID: 11368735]
31. Kim P, Eng TR, Deering MJ, Maxfield A. Published criteria for evaluating health related websites: review. BMJ. 1999;318:647–9.[PMID: 10066209]
32. Murray E, Pollack L, Donelan K, Catania J, Lee K. The impact of health information on the Internet on health care and the physician-patient relationship: national U.S. survey among 1050 U.S. physicians. J Med Internet Res. 2003;5:e17.
33. Belgado BS. Drug information centers on the Internet. J Am Pharm Assoc. 2001;41:631–2.[PMID: 11486993]
34. Dugas M, Weinzierl S, Pecar A, Hasford J. Am J Health Syst Pharm. 2001;58:799–802.[PMID: 11351921]
35. Ruppelt SC, Vann R. Marketing a hospital-based drug information center. 2001;58;1040.
36. Erbele SM, Heck AM, Blankenship CS. Survey of computerized documentation system use in drug information centers. Am J Health Syst Pharm. 2001;58:695–7.[PMID: 11329762]
37. McCreadie SR, Stevenson JG, Sweet BV, Kramer M. Using personal digital assistants to access drug information. Am J Health Syst Pharm. 2002;59:1340–3.[PMID: 12132560]
38. Brody JA, Camamo JM, Maloney ME. Implementing a personal digital assistant to document clinical interventions by pharmacy residents. Am J Health Syst Pharm. 2001;58:1520–2.[PMID: 11515349]
39. Barrons R. Evaluation of personal digital assistant software for drug interactions. Am J Health Syst Pharm. 2004;61:380–5.[PMID: 15011766]
40. Silva MA, Tataronis GR, Maas B. Using personal digital assistants to document pharmacist cognitive services and estimate potential reimbursement. Am J Health Syst Pharm. 2003;60:911–5.[PMID: 12756942]
41. Reilly JC, Wallace M, Campbell MM. Tracking pharmacist interventions with a hand-held computer. Am J Health Syst Pharm. 2001;58:158–61.[PMID: 11202540]
42. Lau A, Balen RM, Lam R, Malyuk DL. Using a personal digital assistant to document clinical pharmacy services in an intensive care unit. Am J Health Syst Pharm. 2001;58:1229–32.[PMID: 11449881]
43. Lynx DH, Brockmiller HR, Connelly RT, Crawford SY. Use of PDA-based pharmacist intervention system. Am J Health Syst Pharm. 2003;60:2341–4.[PMID: 14652983]
44. Grasso BC, Genest R, Yung K, Arnold C. Reducing errors in discharge medication lists by using personal digital assistants. Psychiatr Serv. 2002;53:1325–6.[PMID: 12364687]
45. Clark JS, Klauck JA. Recording pharmacists' interventions with a personal digital assistant. Am J Health Syst Pharm. 2003;60:1772–4.[PMID: 14503114]
46. Clauson KA, Seamon MJ, Clauson AS, Van TB. Evaluation of drug information databases for personal digital assistants. Am J Health Syst Pharm. 2004;61:1015–24.[PMID: 15160777]
47. Lowry CM, Kkostka-Rokosz MD, McCloskey WW. Evaluation of personal digital assistant drug information databases for the managed care pharmacist. J Manag Care Pharm. 2003;9:441–8.[PMID: 14613442]
48. Elson RB, Connelly DP. Computerized medical records in primary care and their role in mediating guideline-driven physician behavior change. Arch Fam Med. 1995;4:698–705.[PMID: 7620600]
49. Evans RS, Pestotnik SL, Classen DC, Clemmer TP, Weaver LK, Orme JF, Jr. et al. A computer-assisted management program for antibiotics and other anti-infective agents. N Engl J Med. 1998;338:232–8.[PMID: 9435330]
50. Hunt DL, Haynes RB, Hanna SE, Smith K. Effects of computer-based clinical support systems on physician performance and patient outcomes: a systematic review. JAMA. 1998;280:1339–46.[PMID: 9794315]
51. Rind DM, Kohane IS, Szolovits P, et al. Maintaining the confidentiality of medical records shared over the Internet and world wide web. Ann Intern Med. 1997;127:138–44.[PMID: 9230004]
52. Frisse ME. What is the Internet learning about you while you are learning about the Internet? Acad Med. 1996;71:1064–107.[PMID: 9177639]
53. Giacalone RP, Cacciatore GG. HIPAA and its impact on pharmacy practice. Am J Health Syst Pharm. 2003;60:433–45.[PMID: 12635449]
54. Blank C. Spending on pharmaceuticals will pass $180 billion by 2008. Hosp Pharma Rep. 1998;12:54.
55. Hoffman JM, Shah ND, Vermeulen LC, Hunkler RJ, Hontz KM. Projecting future expenditures—2005. Am J Health Syst Pharm. 2005;62:149–67.[PMID: 15700889]
56. Altman DE. The new medicare prescription drug legislation. N Engl J Med. 350:1:9–10.
57. Institute of Medicine. Insuring America's health: principles and recommendations. Washington, DC; 2004.
58. Opportunities for the community pharmacist in managed care. Special Report. Washington, DC: American Pharmaceutical Association; 1994.
59. Ellrodt G, Cook DJ, Lee J, Cho M, Hunt D, Weingarten S. Evidence-based disease management. JAMA. 1997;278:1687–92.[PMID: 9388089]
60. Vermeulen LC, Beis SJ, Cano SB. Applying outcomes research in improving the medication-use process. Am J Health Syst Pharm. 2000;57:2277–82.[PMID: 11146972]
61. Top 10 areas of research: report on the most popular fields of drug development. Med Ad News. 2003;137:22:S22.
62. Emilien G, Ponchon M, Caldas C, et al. Impact of genomics on drug discovery and clinical medicine. Q J Med. 2000;93:391–423.[PMID: 10874050]
63. Epler GR, Laskaris LL. Individualization health care and the pharmaceutical industry. Am J Health Syst Pharm. 2001;58:1042.[PMID: 11402480]
64. Special feature: direct-to-consumer advertising. Med Mark Media. 1996;15:8.
65. Piturro M. D-T-C thrives. Managed Health Care News. 1998;14:1.
66. Young D. FDA examines direct-to-consumer advertising data. Am J Health Syst Pharm. 2003;60:2420–1.[PMID: 14686217]
67. Basara LR. The impact of a direct-to-consumer prescription medication advertising campaign on new prescription volume. Drug Inf J. 1996;30:715–29
68. Larner AJ. Use of Internet medical websites and of NHS direct by neurology outpatients before consultation [abstract]. J Neurol Neurosurg Psychiatry. 2002;72:140.
69. Silberg W, Lundberg GD, Musacchio RA. Assessing, controlling, and assuring the quality of medical information on the Internet. JAMA. 1997;277:1244–5.[PMID: 9103351]
70. Wyatt J. Measuring quality and impact on the world wide web. BMJ. 1997;314:1879–81.[PMID: 9224133]
71. Practice and Policy Guidelines Panel, National Institutes of Health Office of Alternative Medicine. Clinical practice guidelines in complementary and alternative medicine an analysis of opportunities and obstacles. Arch Fam Med. 1997;6:149–54.
72. McQueen CE, Shields KM, Generali JA. Motivations for dietary supplement use. Am J Health Syst Pharm. 2003;60:655.[PMID: 12701546]
73. Pal S. Herbal sales reach mainstream market. US Pharm. 1999;24:12.
74. Eisenberg DM, Davis RB, Ettner SL, et al. Trends in alternative medicine use in the United States, 1990–1997: results of a national survey. JAMA. 1998:280:1569–75.
75. Shields KM, McQueen CE, Bryant PJ. National survey of dietary supplement resources at drug information centers. J Am Pharm Assoc. 2004;44:36–40.[PMID: 14965151]
76. West PM, Lodolce AE, Johnston AK. Telephone service for providing consumers with information on herbal supplements. Am J Health Syst Pharm. 2001;58:1842–6.[PMID: 11596701]
77. Meade V. Patient medication information hotlines multiply. Am Pharm. 1991;NS31:569–71.
78. Troutman WG. Consensus-derived objectives for drug information education. Drug Inf J. 1994;28:791–6.
79. Ferrill MJ, Norton LL. Drug information to biomedical informatics: a three tier approach to building a university system for the twenty-first century. Am J Pharm Edu. 1997;61:81–6.
80. Gora-Harper ML, Brandt B. An educational design to teach drug information across the curriculum. Am J Pharm Educ. 1997;61:296–302.
81. Miller S, Clarke A. Impact of postdoctoral specialty residencies in drug information on graduates' career paths. Am J Health Syst Pharm. 2002;59:961–3.[PMID: 12040736]
82. Forrester LP, Scoggin JA, Valle RD. Pharmacy management company-negotiated contract for drug information services. Am J Health Syst Pharm. 1995;52:1074–7.[PMID: 7656096]
83. Fox ER, Tyler LS. Managing drug shortages: seven years' experience at one health-system. Am J Health Syst Pharm. 2003;60:245–53.[PMID: 12613233]
84. Woodruff AE, Hunt CA. Involvement in medical informatics may enable pharmacists to expand their consultation potential and improve the quality of health care. Ann Pharmacother. 1992;26:100–4.[PMID: 1606329]
85. Vanscoy GJ, Gajewski LK, Tyler LS, Gora-Harper ML, Grant KL, May JR. The future of medication information practices: a consensus. Ann Pharmacother. 1996;30:876–81.[PMID: 8826577]
86. Warren PN. Pharmacists to the fore. Managed Health Care News. 1997;13:20H–20I.
87. Zinberg S. Practice guidelines—a continuing debate. Clin Obstet Gynecol. 1998;41:343–7.[PMID: 9646966]
88. Field JM, Lohr KN, editors. Guidelines for clinical practice: from development to use. Washington, DC: National Academy Press; 1992.
89. Harrison MAJ, Draugalis JR, Slack MK, Langley PC. Cost-effectiveness of regional poison control centers. Arch Intern Med. 1996;156:2601–8.[PMID: 8951304]
90. Gong SD, Millares M, VanRiper KB. Drug information pharmacists at health-care facilities, universities, and pharmaceutical companies. Am J Hosp Pharm. 1992;49:1121–30.[PMID: 1595739]
91. Riggins JL. Pharmaceutical industry as a career choice. Am J Health Syst Pharm. 2002;59:2097–8.[PMID: 12434723]
92. Overstreet KM. Medical education and communication companies: career options for pharmacists. Am J Health Syst Pharm. 2003;60:1896–7.[PMID: 14521042]
93. Moghadam RG. Scientific writing: a career for pharmacists. Am J Health Syst Pharm. 2003;60:1899–1900.[PMID: 14521044]
Copyright ©2007 The McGraw-Hill Companies. All rights reserved.
Privacy Notice. Any use is subject to the Terms of Use and Notice. Additional Credits and Copyright Information.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment